Enhanced external counterpulsation in patients with heart failure: a multicenter feasibility study

Area of Science:

• Cardiology
• Cardiovascular Medicine
• Medical Devices

Background:

• Heart failure (HF) significantly impacts patient quality of life and exercise capacity.
• Current treatments for stable heart failure may not fully address functional limitations.
• Enhanced external counterpulsation (EECP) is a non-invasive therapy with potential benefits for cardiovascular conditions.

Purpose of the Study:

• To evaluate the safety and feasibility of using EECP in patients with stable heart failure.
• To assess the impact of EECP on exercise capacity and quality of life in heart failure patients.

Main Methods:

• A cohort of 26 patients with stable heart failure (NYHA classes II-III, LVEF ≤35%) received EECP therapy.
• Treatment involved 1 hour daily, 5 days a week, for a total of 35 hours.
• Patients were monitored for safety (adverse events, lab parameters) and assessed for exercise capacity and quality of life for 6 months post-treatment.

Main Results:

• EECP administration was safe and well-tolerated, with no significant adverse events reported.
• Patients demonstrated significant improvements in exercise capacity, including peak oxygen uptake and exercise duration.
• Quality of life assessments showed significant positive changes at 1 week and 6 months after EECP completion.

Conclusions:

• EECP is a safe and feasible treatment option for patients with stable heart failure.
• The observed improvements in exercise capacity and quality of life support the use of EECP in this population.
• A randomized, controlled trial of EECP for stable heart failure is recommended to further validate these findings.